NCT07542041Recruiting
Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens
Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens (ANoPs)
Source: ClinicalTrials.gov · Last updated 18 Aug 2026
Brief summary (registry, in English)
The goal of this clinical study is to evaluate whether the NEO-Match® test, based on ARTIDIS nanomechanical profiling technology, can help predict treatment outcomes and improve clinical decision-making in patients with suspected pancreatic cancer undergoing biopsy. The main questions this study aims to answer are: * Can the NEO-Match® test predict how patients respond to neoadjuvant (pre-surgical) treatment for pancreatic cancer? * How well does the NEO-Match® test detect malignant pancreatic lesions compared to standard histopathological assessment? This is a prospective, single-arm study. Researchers will compare results from the NEO-Match® test with standard clinical outcomes, imaging findings, and pathology results to evaluate its predictive and diagnostic performance. Participants will: * Undergo a standard-of-care pancreatic biopsy or surgical procedure * Provide an additional biopsy sample for research analysis using the ARTIDIS ART-1 device * Continue to receive standard treatment and care, which is not influenced by the study * Have clinical data, imaging results, and treatment outcomes collected * Be followed every 3 months for up to 2 years The study does not involve experimental treatment or changes to standard medical care. The information collected may help improve future diagnosis, prognosis, and treatment selection for patients with pancreatic cancer.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- First submitted
- 14 Apr 2026
- Start date
- 17 Apr 2026
- Primary completion date
- May 2028
- Lead sponsor
- ARTIDIS AG
- Diseases
- Pancreatic cancer
- NCT number
- NCT07542041
What you commit to
- Study type: Interventional
- Planned participants: 200
- From 17 Apr 2026 to the primary completion date, May 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any condition that, in the opinion of the investigator, makes the subject unsuitable for participation in the study
Who the study is looking for
- Age ≥ 18 years
- Ability to understand and willingness to sign a written informed consent form
- Clinical indication for fine needle biopsy (FNB) of a suspicious pancreatic lesion accessible for biopsy
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Moffitt Cancer Center Coordinator of this site? Confirm its status | Tampa | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.